MELD 3.0

End-stage liver disease — UNOS allocation score (2023)
Sex
Total bilirubin
INR
Serum creatinine
Serum sodium (mEq/L)
Serum albumin
Dialysis ≥ 2× (or 24 h CVVHD) in the past week
Enter bilirubin, INR, creatinine, sodium, and albumin to calculate

About this score

When to use

Estimates short-term mortality in end-stage liver disease; OPTN/UNOS adopted it in July 2023 to prioritise adults for liver allocation, replacing MELD-Na. ⁦[1, 2]⁩

Pearls and pitfalls

• It adds female sex and albumin to MELD-Na, with sodium–bilirubin and albumin–creatinine interaction terms; discrimination improved, particularly for women. ⁦[1]⁩
• Bounds used here: values below 1.0 count as 1.0, creatinine is capped at 3.0 (3.0 also with dialysis), albumin bounded to 1.5–3.5 and sodium to 125–137; the result runs from 6 to 40. ⁦[2]⁩
Summarised from the numbered sources under Evidence. Check the source before relying on a statement.
Evidence
[1] Original publication
Kim WR, Mannalithara A, Heimbach JK, et al. MELD 3.0: the Model for End-Stage Liver Disease updated for the modern era. Adds female sex and serum albumin to MELD-Na and adds sodium–bilirubin and albumin–creatinine interaction terms; improved mortality discrimination, particularly for women.
Gastroenterology, 2021
Open source
[2] Note on this tool
Adopted by OPTN/UNOS for adult liver-allocation prioritisation in July 2023, replacing MELD-Na. Bounds used here: labs ≥ 1.0; creatinine ≤ 3.0 (or 3.0 if dialysis ≥ 2×/week); albumin 1.5–3.5; sodium 125–137; final score 6–40.
Last reviewed: 2026-10
Report an error in this calculator
MedScore is an educational and clinical decision-support tool. It does not provide a diagnosis, a treatment, or a drug-dosing recommendation, and it does not replace clinical judgement or local guidelines. Confirm every result against the original source before acting on it. The treating clinician remains responsible for all decisions.
Support the developer
MedScore is free on the web and made by a medical student. If it helps you, you can support its development.
Support MedScore